Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...
Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Sotagliflozin was linked to lower HbA1c for users with ...
An FDA panel on Thursday recommended against sotagliflozin as an adjunct to insulin for patients with type 1 diabetes (T1D) and mild-to-moderate chronic kidney disease (CKD). With a vote of 11-3, the ...
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback